

PKHD1L1, A Gene Involved in the Stereocilia Coat, Causes Autosomal Recessive Nonsyndromic Hearing Loss

Shelby E. Redfield^{1,+}, Pedro De-la-Torre^{2,3,+}, Mina Zamani^{4,5,++}, Hanjun Wang^{6,++}, Hina Khan⁷, Tyler Morris², Gholamreza Shariati^{5,8}, Majid Karimi⁹, Margaret A. Kenna^{1,2}, Go Hun Seo¹⁰, Hongen Xu⁶, Wei Lu¹¹, Sadaf Naz⁷, Hamid Galehdari⁴, Artur A. Indzhykulian^{2,3,*}, A. Eliot Shearer^{1,3,*}, Barbara Vona^{12,13,*}

1. Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, 300 Longwood Avenue, BCH-3129, Boston, MA 02115, USA

2. Mass Eye and Ear, Eaton Peabody Laboratories, Boston, Massachusetts, USA

3. Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA

4. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

5. Narges Medical Genetics and Prenatal Diagnosis Laboratory, Kianpars, Ahvaz, Iran

6. Precision Medicine Center, Academy of Medical Science, Zhengzhou University, No. 40 Daxuebei Road, Zhengzhou, 450052, China

7. School of Biological Sciences, University of the Punjab, Quaid-e-Azam Campus, Lahore 54590, Pakistan

8. Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

9. Khuzestan Cochlear Implantation Center (Tabassom), Ahvaz, Iran

10. 3billion, Inc., Seoul, South Korea

11. Department of Otorhinolaryngology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jian-she Road, Zhengzhou, 450052, China

12. Institute of Human Genetics, University Medical Center Göttingen, 37073 Göttingen, Germany

13. Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen, 37075 Göttingen, Germany

* Corresponding authors: Artur_Indzhykulian@hms.harvard.edu, Eliot.Shearer@childrens.harvard.edu, barbara.vona@med.uni-goettingen.de

+ Contributed equally to this work

++ Contributed equally to this work

1 ^ *Contributed equally to this work*

2

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

1 **ORCID**

2 Shelby E. Redfield 0000-0002-3485-6654

3 Pedro De-la-Torre 0000-0002-2434-3345

4 Mina Zamani 0000-0002-7005-3787

5 Sadaf Naz 0000-0002-1912-0235

6 Artur A. Indzhukulian 0000-0002-2076-6818

7 A. Eliot Shearer 0000-0002-5324-4805

8 Barbara Vona 0000-0002-6719-3447

9

1 Abstract

2 Identification of genes associated with nonsyndromic hearing loss is a crucial endeavor given
3 the substantial number of individuals who remain without a diagnosis after even the most
4 advanced genetic testing. *PKHD1L1* was established as necessary for the formation of the
5 cochlear hair-cell stereociliary coat and causes hearing loss in mice and zebrafish when
6 mutated. We sought to determine if biallelic variants in *PKHD1L1* also cause hearing loss in
7 humans.

8 Exome sequencing was performed on DNA of four families segregating autosomal recessive
9 nonsyndromic sensorineural hearing loss. Compound heterozygous
10 p.[(Gly129Ser)];p.[(Gly1314Val)] and p.[(Gly605Arg)];p[(Leu2818TyrfsTer5)], homozygous
11 missense p.(His2479Gln) and nonsense p.(Arg3381Ter) variants were identified in *PKHD1L1*
12 that were predicted to be damaging using *in silico* pathogenicity prediction methods. *In vitro*
13 functional analysis of two missense variants was performed using purified recombinant
14 *PKHD1L1* protein fragments. We then evaluated protein thermodynamic stability with and
15 without the missense variants found in one of the families and performed a minigene splicing
16 assay for another variant. *In silico* molecular modelling using AlphaFold2 and protein sequence
17 alignment analysis were carried out to further explore potential variant effects on structure. *In*
18 *vitro* functional assessment indicated that both engineered *PKHD1L1* p.(Gly129Ser) and
19 p.(Gly1314Val) mutant constructs significantly reduced the folding and structural stabilities of
20 the expressed protein fragments, providing further evidence to support pathogenicity of these
21 variants. Minigene assay of the c.1813G>A p.(Gly605Arg) variant, located at the boundary of
22 exon 17, revealed exon skipping leading to an in-frame deletion of 48 amino acids. *In silico*
23 molecular modelling exposed key structural features that might suggest *PKHD1L1* protein
24 destabilization.

25 Multiple lines of evidence collectively associate *PKHD1L1* with nonsyndromic mild-moderate to
26 severe sensorineural hearing loss. *PKHD1L1* testing in individuals with mild-moderate hearing
27 loss may identify further affected families.

28

29 **Keywords:** Polycystic Kidney and Hepatic Disease 1-Like 1 (*PKHD1L1*), stereocilia, deafness

30 Introduction

31 Hearing loss-associated genes are implicated in the function of all parts of the delicate
32 molecular machinery that permits human hearing. The inner hair cells (IHCs) and outer hair
33 cells (OHCs) of the organ of Corti contain an apical bundle of ~100 actin-filled protrusions called
34 stereocilia. Upon sound stimulation, stereocilia bundles are deflected by pressure-induced
35 waves within the fluid-filled organ of Corti. Housing the mechanotransduction apparatus at the
36 tips of stereocilia, these bundles mediate the transformation of the mechanical stimulus into an
37 electrical signal the brain interprets as sound. While IHCs convert sound waves into nerve
38 signals, OHCs allow for non-linear amplification of the sound stimuli by changing their length in
39 response to bundle deflection, a process known as electromotility (Brownell 1990). Although
40 IHCs and OHCs have two separate and distinct functions, both sensory cell types require a
41 properly organized, functional stereocilia bundle. Stereocilia have a transiently expressed
42 surface coat that was first observed in the 1980s as an electron dense material (Santi and
43 Anderson 1987; Slepecky and Chamberlain 1985), but little is understood about the function or
44 molecular architecture of this surface specialization. To date, there are over 30 genes reported
45 to be critical for stereocilia bundle morphology that are associated with sensorineural hearing
46 loss (SNHL) in humans (Michalski and Petit 2015; Petit and Richardson 2009).

47 One such stereocilia protein, polycystic kidney and hepatic disease 1-like 1 (PKHD1L1), also
48 called fibrocystin-L, is critical for hearing in mice (Wu et al. 2019). The *PKHD1L1* gene in
49 humans encodes a 4,243 amino acid protein, which is predicted to be composed by a large
50 extracellular domain, a 20 amino acid transmembrane domain, and a very short cytoplasmic
51 domain of 8 residues. In mice, PKHD1L1 is highly enriched in both IHCs and OHCs, particularly
52 at the tips of OHC stereocilia bundles (Wu et al. 2019). It is hypothesized that this protein makes
53 up the majority of the transient stereocilia coat observed on the surface of hair cell stereocilia
54 membrane. Mice lacking *Pkdh1l1* displayed elevated auditory brainstem responses (ABR) and
55 distortion product otoacoustic emissions (DPOAE) thresholds in response to pure tone stimuli in
56 a progressive fashion (Wu et al. 2019), and lacked the stereocilia coat. More recent data from
57 zebrafish (*Danio rerio*, *Dr*) with a double knockout of *pkhd1l1a* and *pkhd1l1b* (orthologs of
58 human (*Hs*) *PKHD1L1*) show significant deficits in auditory startle responses at the larval stage,
59 consistent with an early-onset auditory phenotype in zebrafish (Makrogkikas et al. 2023). Based
60 on these findings in animal models, we sought to determine whether variants in *PKHD1L1*
61 cause hearing loss in humans.

62 In this study, we propose defects of *PKHD1L1* as causal for autosomal recessive nonsyndromic
63 hearing loss in humans. We describe four unrelated families with biallelic variants in *PKHD1L1*
64 identified via exome sequencing. All four probands presented bilateral congenital SNHL which is
65 nonsyndromic and mild-moderate to severe. In addition, *in vitro* functional evaluation of two
66 missense variants in protein fragments show decreased stabilities, suggesting that they may
67 negatively impact their structures and molecular assembly *in vitro*, while a minigene assay of
68 the c.1813G>A variant reveals aberrant splicing.

69 **Methods**

70 **Recruitment and clinical assessment**

71 This study was approved by the institutional review boards of Boston Children's Hospital (IRB P-
72 00031494), University Medical Center Göttingen (No. 3/2/16), and the School of Biological
73 Sciences, University of Punjab, Lahore, Pakistan (IRB No. 00005281). Written informed consent
74 was obtained from participating members of the four families or parents for their minor children.

75 The proband in family 1 derived from non-consanguineous parents and was ascertained as part
76 of a cohort of 389 pediatric patients with SNHL in the United States. This cohort mostly includes
77 individuals who were born to non-consanguineous parents (three probands with consanguinity
78 reported). Any individual with SNHL was eligible for inclusion in the cohort regardless of SNHL
79 laterality or severity, family history of SNHL, or presence of syndromic features. Two hundred
80 forty-five probands had no prior genetic testing at the time of ascertainment, while 144 probands
81 had some previous nondiagnostic genetic testing (variable methodologies). The proband in
82 family 2 was derived from consanguineous parents who were first-degree cousins and was
83 ascertained as part of a large ethnically diverse Middle Eastern population rare disease study
84 consisting of approximately 800 probands with the sole inclusion criteria being hereditary
85 hearing impairment. The proband in family 3 was born to consanguineous parents and identified
86 from a special education school. The parents did not participate in the study. This proband is
87 part of a cohort of 62 individuals with moderate to severe hearing loss who were born to
88 consanguineous parents with no previous history of deafness in their families. The proband in
89 family 4 was derived from non-consanguineous parents and sequenced as part of an Asian
90 hearing loss cohort. This set is comprised of a total of 1450 hearing loss probands and it
91 includes syndromic and non-syndromic hearing loss. Most of the cohort was first tested by a
92 lab-developed multiplex PCR kit covering the total coding sequencing of *GJB2*, *SLC26A4*, and
93 *MT-RNR1* (described in a previous study (Zeng et al. 2022b)), as these are the most common

94 causative genes in this population. If negative, exome sequencing was performed (the so-called
95 step-wise approach as described previously (Zeng et al. 2022b)). A fraction of patients chose
96 exome sequencing as the first-tier test, while others with negative multiplex PCR were not
97 tested by exome sequencing if DNA from both parents was not available. The proband in family
98 4 was identified from a subset of 449 probands for whom exome sequencing data were
99 available.

100 Demographic, otolaryngologic, audiological, and relevant medical data were ascertained from
101 the medical records of probands. Affected individuals underwent a complete otologic evaluation.
102 Routine pure-tone audiometry was performed according to current standards in all probands
103 and measured hearing thresholds at 0.25, 0.5, 1, 2, 4, 6, and 8 kHz. The probands in families 1
104 and 2 underwent tympanometry and speech audiometry testing, while the proband in family 4
105 underwent tympanometry. Probands 2 and 4 additionally underwent otoacoustic emissions
106 testing. Pure-tone audiometry for proband 3 was performed in ambient noise conditions due to
107 lack of soundproof testing environment.

108

109 **Exome sequencing**

110 Genomic DNA (gDNA) from individuals in families 1 (I:1, I:2 and II:1), 2 (I:1, I:2, II:1 and II:2), 3
111 (II:1), and 4 (I:1, I:2 and II:1) was isolated from either buccal mucosa or whole blood using
112 standard procedures.

113 *Family 1:* Exome sequencing was performed in a Clinical Laboratory Improvements
114 Amendments (CLIA)-certified environment (GeneDx, Gaithersburg, MD, USA). Analysis was
115 performed using the DRAGEN pipeline (Illumina, San Diego, CA, USA). Copy number variants
116 (CNVs) were called using the DRAGEN CNV pipeline and a normalized segmented depth of
117 coverage model, as previously described (Rockowitz et al. 2020).

118 *Family 2:* Exome sequencing was applied to the DNA sample of the proband by MacroGen.
119 Briefly, the sample was subjected to exome enrichment with the SureSelect Target Enrichment
120 v6 kit (Agilent Technologies, Santa Clara, CA, USA), followed by sequencing with Illumina
121 NovaSeq 6000 (Illumina, San Diego, CA, USA) using standard protocols. Then, short reads
122 were aligned to the human genome reference version B38 using BWA and duplicate reads were
123 marked using Picard. GATK and ANNOVAR were used for variant detection and annotation,
124 respectively. Variant filtering and assessment was performed as previously described with slight
125 modifications as described in the variant validation and assessment section (Vona et al. 2021).

126 CNVs were called using a read-depth based in-house tool, including exomeCopy (Love et al.
127 2011) and exomeDepth R packages (Plagnol et al. 2012). CNVs were predicted using a model
128 of the normalized read depth.

129 *Family 3:* Exome sequencing for the proband was carried out at 3billion, Inc., Seoul, South
130 Korea (<https://3billion.io/index>). Briefly, coding exon regions of human genes (~22,000) were
131 captured by xGen Exome Research Panel v2 (Integrated DNA Technologies, Coralville, IA,
132 USA). The captured regions of the genome were sequenced with NovaSeq 6000 (Illumina, San
133 Diego, CA, USA). The raw genome sequencing data analysis, including alignment to the
134 GRCh37/hg19 human reference genome and variant calling and annotation, were conducted
135 with open-source bioinformatics tools including Franklin ([https://franklin.genoox.com/clinical-](https://franklin.genoox.com/clinical-db/home)
136 [db/home](https://franklin.genoox.com/clinical-db/home)) and 3billion in-house software.

137 *Family 4:* Exome sequencing, bioinformatics analysis, and variant filtering for the proband were
138 performed as previously described (Zeng et al. 2022b). Copy number analysis was performed
139 using DECoN (Fowler et al. 2016) with default settings and the BAM files from the same
140 enrichment panel and sequencing run as controls. *STRC* copy number testing was performed
141 using a PCR with exon 22 specific primers as (Vona et al. 2015) previously described, with
142 MLPA analysis.

143

144 **Variant assessment and validation**

145 All exome datasets were assessed without a retrospective search to find *PKHD1L1* biallelic
146 variants. Exome data for the sequenced individuals in families 1, 2, and 3 was filtered to remove
147 all variants with an allele frequency of 0.01 or more in public databases. Coding and splice site
148 variants were retained. Deleteriousness of the missense variants was assigned according to
149 prediction from multiple software and supported by evolutionary conservation of the affected
150 amino acid (Table 1). Due to pedigree structures, homozygous variants were considered first
151 while heterozygous variants were observed later. Additionally, variant analysis of the proband in
152 family 2 employed an in-house database (including more than 2,500 exome datasets). Variants
153 with low allele frequency and deleterious prediction were classified using the hearing loss-
154 adapted ACMG criteria (Oza et al. 2018) and prioritized for further allele segregation studies in
155 the family.

156 Variants in the exome data of proband in family 4 were identified with SnpEff annotation. First,
157 the following variant types were removed from the analysis: intergenic_region,

158 upstream_gene_variant, downstream_gene_variant, 5_prime_UTR_variant,
159 3_prime_UTR_variant, intron_variant, and non_coding_transcript_exon. At the same time,
160 variants with ada_score >0.5 or rf_score >0.5 and variants annotated as likely pathogenic,
161 pathogenic, or VUS in ClinVar were retained. We then filtered out variants with minor allele
162 frequency >0.001 in any population in which at least 2,000 alleles were observed in the
163 gnomAD database (v2.1.1), except those on the ACMG benign stand-alone exception list. We
164 prioritized variants that occurred in the curated hearing loss associated gene list from the
165 ClinGen Hearing Loss Gene Curation Expert Panel (DiStefano et al. 2019).

166 Variants were prioritized based on population and *in silico* pathogenicity software predictions.
167 Variant minor allele frequencies were derived from gnomAD (v2.1.1 and v3.1.2, Table 1) (Chen
168 et al. 2022; Karczewski et al. 2020). Various pathogenicity prediction tools were used including
169 SIFT (Ng and Henikoff 2001), PolyPhen-2 (Adzhubei et al. 2010), FATHMM (Shihab et al.
170 2014), MutationTaster (Schwarz et al. 2014), REVEL (Ioannidis et al. 2016) and CADD
171 (Rentzsch et al. 2019). Variants were analyzed for splice prediction using SpliceAI (Jaganathan
172 et al. 2019), and visualization of amino acid substitution tolerance was supported by the
173 MetaDome web server (Wiel et al. 2019).

174 Variants were annotated using the *PKHD1L1* NM_177531.6 accession number
175 (ENST00000378402.9). The GTEx Portal (Consortium 2013) was referenced for assessing the
176 location of variants across the annotated *Hs PKHD1L1* gene sequence (Supplementary Fig.
177 S1). *PKHD1L1* variant segregation in families 1, 2, and 4 was confirmed using Sanger
178 sequencing, but not for the proband in family 3.

179

180 **Sequence analyses and structural modeling of PKHD1L1 protein**

181 We compared PKHD1L1 protein sequences among 10 different PKHD1L1 orthologs
182 (NM_177531.6 and NP_803875.2 for *Hs* PKHD1L1, see Supplementary Table S1 for more
183 details about the selected species). The sequences were obtained from the National Center for
184 Biotechnology Information (NCBI) protein database (see Supplementary Table S1 for NCBI
185 accession numbers). First, each individual protein sequence was used to predict their signal
186 peptides and domains using the Simple Modular Architecture Research Tool (SMART) (Letunic
187 et al. 2021). Signal peptides were further predicted using the SignalP-5.0 (Almagro Armenteros
188 et al. 2019) and the Prediction of Signal Peptides (PrediSi) online servers (Hiller et al. 2004).
189 AlphaFold2 modelling was used to predict the potential signal peptide cleavage site and

190 accurately inform the start and end of each predicted domain before carrying out the protein
191 sequence alignment (Mirdita et al. 2022). Since the PKHD1L1 Ig-like-plexins transcription
192 factors (IPT) domains do not have a clear conservation pattern at their IPT protein start and end
193 sequence and connecting linker domains, AlphaFold2 modeling results were combined with
194 protein sequence alignment to better predict the signal peptide, IPT domain start and end
195 residue positions, and the location of missense mutations.

196 The ClustalW algorithm (Larkin et al. 2007) on Geneious (Kearse et al. 2012) was used for the
197 sequence identity analysis using the default parameters. Alignment files from Geneious were
198 imported and color-coded in JalView with 35% conservation threshold, as previously described
199 (Kearse et al. 2012). AlphaFold2 simulations of PKHD1L1 fragments were carried out using the
200 Colabfold v1.5.2-patch server using default parameters (Mirdita et al. 2022).

201 202 **Cloning, expression, and purification of engineered bacterially expressed PKHD1L1** 203 **protein fragments and mutant constructs**

204 The cDNA of wild-type (WT) *Mus musculus* (*Mm*) *PKHD1L1* IPT1-3 and IPT5-6 were subcloned
205 into the *NdeI* and *XhoI* sites of the pET21a+ vector. Next, the cDNA fragments were amplified
206 from longer synthesized sequences optimized for *E. coli* expression. Site-directed mutagenesis
207 was applied to engineer the *Mm* PKHD1L1 IPT1-3 p.(Gly129Ser) and PKHD1L1 IPT5-6
208 p.(Gly1314Val) constructs using the QuickChange lightning kit (Agilent Technologies). All
209 constructs were used for protein expression in Rosetta (DE3) competent cells (Novagen) and
210 cultured in TB as reported previously (De-la-Torre et al. 2018). Expressed recombinant proteins
211 were purified under denaturing conditions (6 M guanidine) using nickel beads. Next, their purity
212 was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
213 refolded at 4 °C using previously reported conditions (De-la-Torre et al. 2018), briefly outlined
214 below. WT *Mm* PKHD1L1 IPT1-3 and IPT1-3 p.(Gly129Ser) were refolded by fast or drop-wise
215 dilution as previously reported for other protein families (De-la-Torre et al. 2018): 20 mL of pure
216 denatured protein (0.5-1 mg/mL) was dropped into 480 mL of refolding buffer containing 20 mM
217 TrisHCl [pH 8.0], 150 mM KCl, 50 mM NaCl, 2 mM CaCl₂, 400 mM L-arginine, and 2 mM D(+)
218 glucose. WT *Mm* PKHD1L1 IPT5-6 and IPT5-6 p.(Gly1314Val) were refolded by dialysis of 40
219 mL of eluted denatured protein at 0.5 mg/mL into 1000 mL of refolding buffer (20 mM TrisHCl
220 [pH 7.5], 150 mM KCl, 50 mM NaCl, 5 mM CaCl₂, 400 mM L-arginine, 1 mM of glutathione
221 oxidized). Proteins were concentrated using 10,000 Da Amicon Ultra-15 centrifugal filters and
222 purified using size exclusion chromatography (SEC) with an Akta Purifier System with the S200

223 16/600 pg and S200 13/300 increase GL columns (GE Healthcare) in a buffer containing 20 mM
224 Tris-HCl pH 7.5, 150 mM KCl, 50 mM NaCl, and 5 mM CaCl₂ to preserve the most abundant
225 endolymphatic cations. Following SEC, protein purity was further verified by SDS-PAGE.

226

227 **Nanoscale differential scanning fluorimetry (NanoDSF)**

228 WT *Mm* PKHD1L1 IPT1-3 and IPT5-6 protein fragments and their respective missense IPT1-3
229 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) proteins were used for functional evaluation *in vitro*.
230 Thermodynamic evaluation and folding stabilities of these constructs in solution were carried out
231 using nano differential scanning fluorimetry (NanoDSF). Pure proteins were concentrated to 0.5-
232 1 mg/mL for NanoDSF using a Prometheus NT.48 (Nanotemper) and scanned between 20-95
233 °C with a pre-stabilization phase of 1 min and a temperature slope of 2 °C/min (37 min in total).
234 Data were processed using a PR. ThermControl v2.1.2 software and plotted using GraphPad
235 Prism. At least two biological replicates were used for each experiment. Each protein
236 preparation was independently expressed and refolded at least two time (two biological
237 replicates), and evaluated independently on NanoDSF. Each NanoDSF scan used at least four
238 separate capillary tubes run in parallel for each biological replicate. Each result per biological
239 replicate represents average values of these measurements. Protein folding analysis results
240 were plotted as a relationship of the normalized F350/F330 (%) ratio intensities (T_{onset}). The first
241 derivative of F350/F330 (%) intensities were plotted to obtain the thermal unfolding transition
242 midpoints (T_m).

243

244 **Minigene assay of the c.1813G>A (Gly605Arg) variant**

245 A minigene assay was performed as previously described (Zeng et al. 2022a). Briefly, the WT
246 and mutated sequences (exon 17 and flanking intronic sequences) were cloned (MINI-
247 PKHD1L1-Kpn1-F: 5'-GGTAGGTACCAGGCC-3', 5'-TATGGAACACCAATTTA-3' and MINI-
248 PKHD1L1-BamH1-R: 5'-TAGTGGATCCAAT-3' and 5'-AAGGCCTGTCCTCAAATGTCT-3')
249 following amplification from the DNA of the proband in family 4 between exons A and B in the
250 pcMINI plasmid. Next, the WT and mutated plasmids were transfected into both HEK293 and
251 HeLa cells. The splicing effects were analyzed via RT-PCR and sequencing with vector-specific
252 primers (PcMINI-F: 5'-CTAGAGAACCCACTGCTTAC-3' and PcMINI-R: 5'-
253 TAGAAGGCACAGTCGAGG-3').

254

255 Results

256 Clinical genetics and variant identification

257 **Family 1 (Fig. 1):** The proband is a 11-15-year-old female born to healthy nonconsanguineous
258 parents. She did not pass a newborn hearing screen bilaterally. Pure tone audiometry has been
259 performed approximately every 6 months and consistently demonstrated a slowly progressive
260 mild to moderate SNHL bilaterally. Between the ages of 0-5 years and 11-15 years, there was
261 an increase in pure tone average (PTA) of 5 dB for the right ear and 8 dB for the left ear. PTA_{0.5-}
262 _{4K} was 41.25 and 38.75 in the right and left ears, respectively at age 0-5. Most recent
263 audiometric testing showed PTA of 45.00 and 48.75 in the right and left ears, respectively.
264 Speech audiometry at most recent evaluation (age 11-15 years) demonstrates a 90%-word
265 recognition at a comfortable listening level. Speech recognition threshold (SRT) is 45 dB
266 bilaterally. There was a history of episodes of benign paroxysmal positional vertigo (BPPV)
267 which resolved after Epley maneuver. Imaging studies of the inner ear were not performed. An
268 electrocardiogram and ophthalmology exam were normal. Cytomegalovirus testing performed at
269 11-15-weeks-old was negative. There were no dysmorphic facial features, neurological or
270 developmental abnormalities, or other pertinent history. Exome sequencing was performed with
271 an average depth of coverage of variants of 92 reads with 95.4% of variants covered with more
272 than 20 reads. Exome sequencing revealed candidate variants only in *PKHD1L1* following the
273 variant filtering methodology described. The proband was compound heterozygous for
274 missense variants, c.385G>A, p.(Gly129Ser) and c.3941G>T, p.(Gly1314Val) (Table 1) that
275 segregated within the trio in a Mendelian recessive manner (residue numbering corresponds to
276 the NCBI *Hs* PKHD1L1 sequence NP_803875.2 including the signal peptide, Supplementary
277 Table S1).

278 The c.385G>A, p.(Gly129Ser) substitution resides in exon 4 of 78 in *PKHD1L1* and has a
279 maximum allele frequency (MAF) of 0.001471% in gnomAD (v3.1.2). This variant is predicted to
280 be deleterious to protein structure and function via *in silico* predictors (Table 1). This nonpolar
281 glycine to polar serine substitution occurs at the tip of the PKHD1L1 IPT1 domain (N-terminal
282 end) (Fig. 2b-d). This locus is predicted to be somewhat tolerant to missense substitution
283 (Supplementary Fig. S2). On the other hand, the c.3941G>T, p.(Gly1314Val), located in exon
284 32 of 78 in *PKHD1L1*, has a MAF of 0.07204% (Table 1, gnomAD, v3.1.2). It is suggested to be
285 deleterious to protein structure and function by *in silico* prediction tools (Table 1), as well as

286 predicted to be intolerant to missense substitution (Supplementary Fig. S2). The p.(Gly1314Val)
287 substitution is located at the PKHD1L1 IPT6 domain region (Fig. 2b-e).

288 **Family 2 (Fig. 1):** The proband is a 6-10-year-old male born to healthy consanguineous (first
289 cousin) parents with subjectively normal hearing. Congenital SNHL was suspected that was
290 clinically diagnosed in the first months of life and has progressed to a bilateral moderate to
291 severe degree. Pure tone audiometry shows moderate to severe SNHL in all frequencies.
292 Speech audiometry understanding is 100% at a comfortable listening level, and the otoacoustic
293 emissions were present bilaterally. His SRT is 60 dB and his speech discrimination score (SDS)
294 is 100% at the intensity level of 80 dB. The proband currently uses hearing aids bilaterally.
295 There have been no vestibular abnormalities or delays in motor milestones. Exome sequencing
296 was performed with an average depth of 66X, with 75% of variants covered with more than 20
297 reads. Exome sequencing revealed that the proband was homozygous for the c.10141C>T,
298 p.(Arg3381Ter) nonsense variant (Table 1) that resided in a ~28 Mb run of homozygosity. All
299 other variants were excluded based on segregation (Supplementary Table S2). Sanger
300 sequencing at this locus confirmed the homozygous variant and revealed that the parents were
301 both heterozygous carriers of the c.10141C>T, p.(Arg3381Ter) substitution.

302 The c.10141C>T, p.(Arg3381Ter) variant is located in exon 62 of 78 and identified with a MAF
303 of 0.02067% in population databases (Table 1, gnomAD, v2.1.1). This variant occurs in a region
304 with parallel beta-helix (Pbh1) repeats (Fig. 2b and Supplementary Fig. S3 for residue
305 conservation), introducing a premature stop codon that is predicted to result in the loss of
306 approximately 20% of the transcript (~ 882 amino acids), including the transmembrane domain,
307 and could potentially cause nonsense mediated decay. However, if expressed in a truncated
308 form, lack of the transmembrane domain is likely to impair proper localization of PKHD1L1 in the
309 cell membrane or might induce unconventional secretion of PKHD1L1 protein fragments.

310 **Family 3 (Fig. 1):** The proband is a 11-15-year-old male with congenital SNHL born to healthy
311 consanguineous parents, and her audiometric testing demonstrated a bilateral severe SNHL
312 (PTA_{0.5-4K} 85 dB HL). No further follow up was possible for the affected individual. Exome data
313 had an average overall depth of 211X and 99.1% of variants were covered by more than 20
314 reads. Exome analysis revealed two homozygous missense variants of interest: one in
315 *PKHD1L1* c.7437C>A, p.(His2479Gln) and one in *MYO7A* (NM_000260.4:c.1123C>G,
316 p.(Leu375Val)). Both *MYO7A* and *PKHD1L1* variants were of high quality and each was
317 covered by more than 150 reads. The homozygous variant in *MYO7A*, with a coverage of 198
318 high quality reads, was deprioritized given uncertain and neutral *in silico* predictions with respect

319 to impact on protein structure and function (Supplementary Table S2 and Supplementary Fig.
320 S6). Moreover, the affected amino acid was not conserved in evolution, being isoleucine instead
321 of leucine in some mammals, birds, and amphibians.

322 The c.7437C>A, p.(His2479Gln) substitution in *PKHD1L1* is located in exon 49 of 78 and is
323 identified at a MAF of 0.3107% in population databases (Table 1, gnomAD, v3.1.2). This
324 positively charged histidine to neutral glutamine substitution is located in a topological region
325 with an unpredicted domain structure when using the SMART prediction tool (Fig. 2b).

326 **Family 4 (Fig. 1):** The proband is an 6-10-year-old boy with SNHL born to healthy non-
327 consanguineous parents. He presented in 2023 with concern for hearing loss, and pure tone
328 audiometry demonstrated a bilateral moderate SNHL. DPOAEs were absent in both ears, and
329 the tympanograms were normal, suggesting dysfunction of the outer hair cells. The hearing loss
330 in this proband is thought to be congenital because the father claimed that the hearing was
331 affected from a younger age, but newborn hearing screening was not performed at the time of
332 birth. The father had a pure tone audiometric evaluation at the age of 30-35 years, which
333 showed thresholds within the normal range.

334 The proband underwent exome sequencing at Precision Medicine Center of Zhengzhou
335 University. Exome sequencing was performed with an average depth of 123.7X for all variants,
336 with 99.2% covered by more than 20 reads. The initial exome analysis was negative;
337 sequencing data was reanalyzed after this manuscript was deposited as a preprint in medRxiv
338 (Redfield et al. 2023). Reanalysis revealed compound heterozygous variants in *PKHD1L1*, with
339 the missense variant c.1813G>A, p.(Gly605Arg) inherited from the father, and a frameshift
340 variant c.8452_8468del, p.(Leu2818Tyrf5Ter5) from the mother. The p.(Gly605Arg) missense
341 variant was predicted to affect splicing by multiple tools, including dbNSFP (ada_score of
342 0.9998, and rf_score of 0.893), and SpliceAI (delta score of Donor Gain: 0.23). Interestingly, the
343 same heterozygous missense variant c.1813G>A, p.(Gly605Arg) was found in another
344 genetically undiagnosed proband with congenital bilateral severe SNHL from the Henan
345 cohorts. In addition, the frameshift variant c.8452_8468del, p.(Leu2818Tyrf5Ter5) was also
346 found in a genetically diagnosed proband (heterozygous c.8452_8468del; *MYO7A* c.689C>T,
347 p.(Ala230Val), a known *MYO7A* pathogenic variant,
348 (<https://www.ncbi.nlm.nih.gov/clinvar/variation/178993/>) (Di Leva et al. 2006; Kaneko et al.
349 2017; Lezirovitz and Mingroni-Netto 2022) with congenital bilateral SNHL from the Henan
350 cohorts.

351 **Investigating the conservation of the mutated residue positions throughout evolution**

352 All missense variants do not appear to cluster in any particular region of the *Hs* PKHD1L1 that
353 was used for alignment and further analysis (Supplementary Fig. S1). In comparing the longest
354 PKHD1L1 sequences among 10 different orthologs, we uncovered an overall amino acid
355 sequence identity of 79.2 % (Supplementary Fig. S3). Notably, *Mm* and *Hs* PKHD1L1 share
356 81.8% of amino acid sequence identity (when comparing for identical sites excluding the signal
357 peptides), while *Hs* and *Mm* orthologs of IPT1 and IPT6 shows 82.9% and 77.8%, respectively,
358 suggesting high protein sequence conservation between the two species. Although some
359 previous studies report protein sequence alignments and predictions of PKHD1L1 IPT domains
360 (Hogan et al. 2003), an in-depth analysis was necessary to more accurately predict the signal
361 peptide cleavage sites, as well as the starting and ending residues for each IPT domain. The
362 location of the native Gly126, Gly1314, and His2479 residues, where the reported missense
363 variants were detected, are highly conserved across a diverse set of the 10 different PKHD1L1
364 orthologues analyzed (Fig. 2d-e, Fig. 4a, and Supplementary Fig. S3 and Fig. S4).

365

366 **AlphaFold2 modeling of PKHD1L1 substitutions**

367 PKHD1L1 has 14 predicted IPT extracellular-domain repeats of similar fold but with non-
368 identical protein sequences and labeled as IPT1 to IPT14 from its N-terminal to C-terminal end,
369 and other key domain features (Fig. 2b). The AlphaFold2 model of WT *Hs* IPT1-2 and its mutant
370 p.(Gly129Ser) shows no apparent differences between their predicted structures (Fig. 3a-b),
371 likely because the small side chain carrying this residue is located on a loop region exposed to
372 the solvent. More specifically, the p.(Gly129Ser) variant is located within the connecting loop
373 between the β -strand 6-7 of IPT1, close to a potential disulphide bond formed by p.Cys100 and
374 p.Cys86, also found in plexin-like domains (Fig. 3b). Changes of the polarity or the electrostatic
375 potential of this loop by p.(Gly129Ser) might cause structural changes or altered loop dynamics
376 in IPT1 (Krieger et al. 2005). We also generated AlphaFold2 models for *Hs* IPT5-6 consistent
377 with the expected IPT plexin-like folding for this structure (Fig. 3c-e). According to this structural
378 model, the *Hs* p.(Gly1314Val) mutation is also located at the connecting loop between the β -
379 strand 6-7 of IPT6 (Fig. 3c-e). Furthermore, the p.(Gly1314Val) variant is located within the
380 connecting area between IPT5 and IPT6, and the AlphaFold2 model suggests a structural
381 change for this specific fragment (Fig. 3d-e).

382 In a previous study, authors used protein sequence analysis of PKHD1, PKHD1L1, and TMEM2
383 reporting that PKHD1 and PKHD1L1 share two regions of significant sequence homology with
384 TMEM2 (Hogan et al. 2003). AlphaFold2 modelling of the p.(His2479Gln) variant and

385 surrounding PKHD1L1 region, revealed a high structural homology with a *Hs* TMEM2 protein
386 (Fig. 4). We identified that this region features a conserved p.His2479 residue (throughout 10
387 different PKHD1L1 orthologs, Supplementary Fig. S4) (p.His552 in *Hs* TMEM2, Fig. 4a; Protein
388 Data Bank (PDB): 8C6I (Niu et al. 2023)) reported to form a nickel-finger binding site, which
389 might mediate catalytic functions in TMEM2. Disruption of this site in PKHD1L1 and TMEM2
390 might impair cation binding (Fig. 4a-f and Supplementary Fig. S3 and S4) and suggests a
391 potential deleterious effect for this variant on protein structure and function. This locus is
392 predicted neutral in terms of tolerance to missense substitution (Supplementary Fig. S2).

393

394 **Functional testing of the p.(Gly129Ser) and p.(Gly1314Val) substitutions**

395 Next, we expressed and purified the recombinant WT *Mm* PKHD1L1 IPT1-3 and IPT5-6 protein
396 fragments as well as the respective IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) mutant
397 protein fragments using SEC (Supplementary Fig. S5). These protein constructs represent key
398 regions of the complete extracellular domain of PKHD1L1 where these mutations might locally
399 affect the structural assembly of the protein. The thermodynamic and folding stabilities were
400 measured using NanoDSF to assess the protein stabilities in solution for WT PKHD1L1 protein
401 fragments and compared to fragments carrying missense mutations (Fig. 5 and Supplementary
402 Fig. S5). For WT IPT1-3, the T_{onset} (melting temperature at which unfolding begins) was
403 measured at a maximum of 58 °C, while the T_{onset} for IPT1-3 p.(Gly129Ser) variant was 52 °C (a
404 6 °C decrease, Fig. 5 and Supplementary Fig. S5). In addition, there was a decrease on the T_m
405 (melting temperature or point at which 50% of the protein is unfolded) of ~ 4 °C comparing
406 different thermal transition points between WT and the IPT1-3 p.(Gly129Ser) variant (Fig. 5a).
407 These measurements strongly suggest that the p.(Gly129Ser) variant affects PKHD1L1 protein
408 stability within this region.

409 Similarly, NanoDSF measurements for WT *Mm* PKHD1L1 IPT5-6 and *Mm* IPT5-6
410 p.(Gly1314Val) showed a T_{onset} of 35.48 °C and 28.56 °C, respectively (~ 7 °C decrease, Fig. 5
411 and Supplementary Fig. S5). Additionally, WT *Mm* PKHD1L1 IPT5-6 showed a melting
412 temperature T_m of 45.10 °C, while the mutant IPT5-6 p.(Gly1314Val) displayed a decrease on
413 this T_m to 36.6 °C (decreasing the temperature ~ 8.6 °C) (Fig. 5b). These results confirm that
414 both IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) variants indeed significantly decrease the
415 thermal and folding stabilities of these PKHD1L1 protein fragments.

416

417 **Splicing evaluation of p.(Gly605Arg)**

418 Based on *in silico* evaluation (Table 1), the missense variant p.(Gly605Arg) was predicted to
419 affect splicing given that it occurs at the 3' exon boundary of exon 17 adjacent to the 5' intronic
420 splice donor site of intron 17 (Fig. 6). RNA studies of this variant indicated a functional effect on
421 splicing, leading to an in-frame deletion of 48 amino acids (r.1670_1813del,
422 p.Val557_Arg604del; Fig. 6).

423

424

425 **Discussion**

426 A majority of congenital SNHL is attributable to a genetic etiology, and clinical genetic testing for
427 known SNHL genes is an established standard of care in the diagnostic evaluation of bilateral
428 SNHL in pediatric patients (Shearer and Smith 2015; Smith et al. 2005). To date, there are over
429 120 known genetic causes of nonsyndromic hearing loss, and gene panel tests are
430 recommended to facilitate accurate and timely genetic diagnosis of SNHL
431 (<https://hereditaryhearingloss.org>). However, despite advances in genetic testing for SNHL, the
432 diagnostic yield for SNHL ranges from 22.5% to 55.7% with an average of ~ 40% (Downie et al.
433 2020; Perry et al. 2023; Rouse et al. 2022; Sloan-Heggen et al. 2016). The identification of
434 novel hearing loss genes is critical to improving diagnostic rates, thus impacting care and
435 management for individuals with SNHL.

436 In mice, PKHD1L1 is predominantly expressed in the OHC stereocilia by P0 to P12 with a
437 basal-to-apical (decreasing) expression gradient and is a major component of the stereocilia
438 surface coat (Wu et al. 2019). *Pkhd11*-deficient mice lack the surface coat at the stereocilia tips
439 and exhibit progressive SNHL by ABR and DPOAE measurements starting as early as 3 weeks.
440 Although its function remains largely undetermined, the two functional hypotheses of PKHD1L1
441 expression at the stereocilia include that it may be required for the correct localization of other
442 stereociliary proteins, or it plays a role during the development of attachment crowns at the
443 stereocilia to secure the tectorial membrane to the bundle. An immature attachment could
444 manifest as a persisting relaxed tectorial membrane coupling (Wu et al. 2019). Furthermore, it is
445 unknown whether PKHD1L1 is the only component of the stereocilia coat. Recently, *pkhd11*
446 was shown to play a critical role in regulating hearing in zebrafish (Makrogkikas et al. 2023).
447 *pkhd11* has a ubiquitous expression pattern and is sustained for most of embryonic
448 development (Makrogkikas et al. 2023). Through depletion of the two paralogous genes

449 (*pkhd111a* and *pkhd111b*), double mutant zebrafish exhibited significant hearing loss from the
450 larval stage (6 days post fertilization) which differs compared to progressive hearing loss in the
451 mouse (Wu et al. 2019).

452 Although presenting congenitally in the majority of patients, the degree of hearing impairment in
453 the patients we present is fairly broad: The proband in family 1, with
454 p.[(Gly129Ser)];p.[(Gly1314Val)] compound heterozygous variants, was diagnosed with
455 congenital hearing impairment that remains mild to moderate at the age of 11-15 years; the
456 proband in family 2, with a homozygous p.(Arg3381Ter) variant, already showed moderate to
457 severe SNHL at the age of 6-10 years; and the proband in family 3, at the age of 11-15 years,
458 showed severe hearing impairment attributed to the homozygous p.(His2479Gln) variant.
459 However, in case of the proband in family 3 with the *PKHD1L1* p.(His2479Gln) variant, it is
460 possible that notwithstanding neutral predictions by different software packages (Table 1, and
461 Supplementary Fig. S2), the detected *MYO7A* p.Leu375Val missense variant is pathogenic
462 (Supplementary Table S2) and the *PKHD1L1* variant is an incidental finding. Or, both *MYO7A*
463 and *PKHD1L1* variants may contribute to the more severe hearing loss of this individual.
464 However, AlphaFold2 modelling showed that the *MYO7A* p.Leu375Val variant might not induce
465 structural changes in *MYO7A* (Supplementary Fig. S6). The proband in family 4 with
466 p.[(Gly605Arg)];p.(Leu2818TyrfsTer5)] compound heterozygous variants had a moderate
467 hearing loss at the age of 6-10 years.

468 While we have identified individuals in four families with variants in *PKHD1L1*, this study
469 highlights the necessity for an extended case series with longitudinal audiological follow up and
470 functional studies to assess variant effects of patient-specific perturbations on development,
471 maturation, and function of the auditory system, as well as explore the potential of accelerated
472 effects of age, noise, or trauma on progression of hearing loss, which remain as current major
473 limitations. Interestingly, the *PKHD1L1* gene has been suggested to be associated with
474 adult-onset hearing loss (Lewis et al. 2023). Since the studied variants are also located in
475 different residue positions in the *PKHD1L1* protein sequence, the broad range of hearing
476 impairment from these patients might suggest that these variants differentially impact the protein
477 expression, folding, and/or the stability and function of *PKHD1L1*. Therefore, we cannot exclude
478 an environmental component that may account for variability.

479 We also investigated the conservation of the mutated residue positions throughout evolution.
480 Multiple sequence alignments of the complete *PKHD1L1* amino acid sequence from 10 different
481 orthologs were analysed and found to be highly conserved. This suggests that these native

482 residues might be critical to protein folding and assembly. Therefore, variants in these positions
483 might disrupt protein function and potentially cause hearing impairment *in vivo*.

484 Because the p.(Arg3381Ter) introduces a stop codon that would be predicted to be targeted by
485 nonsense mediated decay by the 50-nucleotide rule (Frischmeyer and Dietz 1999), it is
486 anticipated that this would result in the lack of protein or low yield of truncated protein
487 expression without the transmembrane domain, key for the proper insertion into the cell
488 membrane. This is likely to impair the proper folding, trafficking, and insertion of PKHD1L1 in
489 the stereocilia-plasma membrane, or even result in secretion of PKHD1L1 extracellular
490 fragments that could progressively affect hearing function. Interestingly, secreted versions of
491 extracellular PKHD1L1 have been found in supernatant solution from platelet cells (Maynard et
492 al. 2007) and their soluble concentrations could be modulated by protease inhibitors (Fong et al.
493 2011), suggesting potential cleavage sites in *Hs* PKHD1L1. However, the role of these
494 potentially cleaved extracellular PKHD1L1 protein fragments remains unknown.

495 To further predict how these PKHD1L1 mutant variants might affect the PKHD1L1 protein at the
496 structural level, we modelled the structures of the individual domains carrying reported variants
497 (Fig. 3a-e and Fig. 4b-e). The p.(Gly129Ser) substitution in IPT1 was not predicted to exert an
498 apparent structural difference. We speculate that instead changes of the polarity or the
499 electrostatic potential of the β -strand linker loop by p.(Gly129Ser) might alter loop dynamics in
500 IPT1. Interestingly, both glycine substitutions p.(Gly129Ser) and p.(Gly1314Val) are located
501 within the same connecting loop between β -strand 6-7 in IPT1 and IPT6, respectively. While the
502 AlphaFold2 model of the p.(Gly129Ser) mutant shows no apparent structural changes in the
503 predicted structure (Fig. 3a-b), the AlphaFold2 model of p.(Gly1314Val) shows a conformation
504 change, likely due to steric hindrance on the structure (Fig. 3c-e). Finally, we also mapped the
505 location of the p.(His2479Gln) using structural modeling by AlphaFold2 (Fig. 4, Supplementary
506 Fig. S4). Our results indicate that the His2479 position (among 10 different PKHD1L1 orthologs)
507 is 100% conserved with a *Hs* TMEM2 protein (PDB: 8C6I), a regulator of the hyaluronan
508 metabolism (Fig. 4a and 4e-f) (Sato et al. 2023). Interestingly, experiments suggest that TMEM2
509 activity is calcium-dependent (Yamamoto et al. 2017) and TMEM2 has been previously studied
510 for its structural similarities with the *CEMIP* deafness gene candidate (Yoshida et al. 2013).

511 Our NanoDSF thermal folding analysis showed that both T_{onset} and T_m values decreased in the
512 presence of the p.(Gly129Ser) and p.(Gly1314Val) variants. The T_m measurements using
513 NanoDSF showed p.(Gly129Ser), located in a loop, decreases the stability of IPT1 and further
514 showed how this variant propagates its destabilizing effects to the neighboring IPT2 and IPT3

515 (Fig. 2b, Fig. 5, and Supplementary Fig. S5). Likely, the p.(Gly1314Val) variant also alters the
516 stability of the loop and the chemical environment in the IPT5-IPT6 connection, since the
517 measured folding stability showed an 8.6 °C decrease of unfolding temperature between WT
518 IPT5-6 fragment and the p.(Gly1314Val) variant (Fig. 5). This is the first study showing strong
519 evidence to support how missense variants locally affect the structural folding and stability of
520 PKHD1L1 fragments *in vitro*. Given the high conservation rate of 81.8% in amino acid sequence
521 identity between the *Hs* and *Mm* PKHD1L1 (excluding the 20 amino acid long signal peptide
522 according to SMART, Supplementary Fig. S3), and the 100% conservation of the mutated sites
523 across the species analyzed, we believe our findings using *Mm* PKHD1L1 protein fragments
524 can be directly applied to *Hs* PKHD1L1. Future functional studies involving highly conserved
525 full-length PKHD1L1 orthologs and their protein purification would allow for better understanding
526 of various effects such variants might have on the stability of the entire PKHD1L1 extracellular
527 domain, its protein expression and proper localization, which might be linked to the progression
528 and hearing loss severity. Furthermore, studies focused on uncovering the influence of
529 mutations on the structure of the complete PKHD1L1 extracellular domain will help to better
530 understand the role of PKHD1L1 in hearing function and beyond, since the PKHD1L1 has been
531 suggested as a tumor suppressor (Yang et al. 2023) and a human cancer biomarker (Kafita et
532 al. 2023; Wang et al. 2023; Zheng et al. 2019).

533 As we have shown that single point mutations have a detrimental effect on protein folding and
534 stability in protein fragments using NanoDSF, the deletion of longer protein motifs in PKHD1L1
535 extracellular domain might contribute to a more detrimental effect. In this case, the *in vitro*
536 evidence presented in this study for the PKHD1L1 p.(Gly605Arg) missense variant found in the
537 proband of family 4 (Fig. 1, inherited from the father), strongly supports that this post-
538 transcriptional splicing modification leads to an in-frame deletion of 48 amino acids
539 (p.Val557_Arg604) (Fig. 6). This could explain the more significant hearing deficit caused by the
540 p.(Gly605Arg) splicing mutation along with the frameshift variant c.8452_8468del,
541 p.(Leu2818TyrfsTer5) (inherited from the mother) in the same individual, compared to the milder
542 hearing loss phenotype presented in the proband in family 1 (compound heterozygous
543 p.[(Gly129Ser)];p.[(Gly1314Val)]).

544 Additional syndromic involvement was excluded in all four probands. However, in addition to
545 hearing impairment, disruption of PKHD1L1 has also been associated with increased
546 susceptibility to pentylenetetrazol-induced seizures in mice indicating a possible role in
547 maintenance of neuronal excitability in the central nervous system (Yu et al. 2023). It is currently

548 unknown whether defects in *PKHD1L1* might cause sensory auditory seizures. However,
549 *PKHD1L1* is expressed in the hippocampus and cerebral cortex in adult WT mice. Knockdown
550 of *PKHD1L1* using *PKHD1L1*-shRNA or *PKHD1L1*-shRNA-AAV increased susceptibility of
551 seizures as indicated by increased epileptiform bursting activity in cultured hippocampal
552 neurons and pentylenetetrazol-induced seizures of mice following knockdown, suggesting a role
553 for *PKHD1L1* in the maintenance of normal excitation-inhibition balance (Yu et al. 2023).
554 Knockdown of *PKHD1L1* led to the downregulation of both expression and function of the KCC2
555 membrane protein, which may explain the increased susceptibility to seizures (Yu et al. 2023).
556 There is no evidence that mutations in *PKHD1L1* lead to seizures in humans, though an open
557 question remains as to whether similar pleiotropic effects paralleling, for example, the various
558 phenotypes caused by pathogenic variants in *TBC1D24* may also occur as more *PKHD1L1*
559 patients are discovered (Mucha et al. 1993; Rehman et al. 2017).

560 **Conclusion**

561 Here we provide data to support that mutations in *PKHD1L1* cause human nonsyndromic
562 autosomal recessive congenital, mild-moderate to severe SNHL. We demonstrated that all
563 reported missense variants point to highly conserved residues throughout evolution, suggesting
564 that the native residues are key for protein folding and function, while variants in these sites
565 locally affect the thermal-folding stability of *PKHD1L1* fragments in solution. Inclusion of
566 *PKHD1L1* as a hearing loss gene is supported by four families segregating plausible variants, *in*
567 *vitro* functional data confirming their detrimental impact, as well as previously published mouse
568 and zebrafish models demonstrating hearing loss. This study serves as a call to clinical
569 laboratories to include careful screening of *PKHD1L1* biallelic variants in patients with a hearing
570 loss ranging from mild-moderate to severe. Further research will be needed to determine the
571 effect of age, noise, or trauma on the potential progression of *PKHD1L1* linked hearing loss.

References

- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. *Nat Methods* 7: 248-9. <https://doi.org/10.1038/nmeth0410-248>
- Almagro Armenteros JJ, Tsirigos KD, Sonderby CK, Petersen TN, Winther O, Brunak S, von Heijne G, Nielsen H (2019) SignalP 5.0 improves signal peptide predictions using deep neural networks. *Nat Biotechnol* 37: 420-423. <https://doi.org/10.1038/s41587-019-0036-z>
- Brownell WE (1990) Outer hair cell electromotility and otoacoustic emissions. *Ear Hear* 11: 82-92. <https://doi.org/10.1097/00003446-199004000-00003>
- Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, Alföldi J, Watts NA, Vittal C, Gauthier LD, Poterba T, Wilson MW, Tarasova Y, Phu W, Yohannes MT, Koenig Z, Farjoun Y, Banks E, Donnelly S, Gabriel S, Gupta N, Ferreira S, Tolonen C, Novod S, Bergelson L, Roazen D, Ruano-Rubio V, Covarrubias M, Llanwarne C, Petrillo N, Wade G, Jeandet T, Munshi R, Tibbetts K, Consortium gP, O'Donnell-Luria A, Solomonson M, Seed C, Martin AR, Talkowski ME, Rehm HL, Daly MJ, Tiao G, Neale BM, MacArthur DG, Karczewski KJ (2022) A genome-wide mutational constraint map quantified from variation in 76,156 human genomes. *bioRxiv*: 2022.03.20.485034. <https://doi.org/10.1101/2022.03.20.485034>
- Choudhary D, Narui Y, Neel BL, Wimalasena LN, Klanseck CF, De-la-Torre P, Chen C, Araya-Secchi R, Tamilselvan E, Sotomayor M (2020) Structural determinants of protocadherin-15 mechanics and function in hearing and balance perception. *Proc Natl Acad Sci U S A* 117: 24837-24848. <https://doi.org/10.1073/pnas.1920444117>
- Consortium G (2013) The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 45: 580-5. <https://doi.org/10.1038/ng.2653>
- De-la-Torre P, Choudhary D, Araya-Secchi R, Narui Y, Sotomayor M (2018) A Mechanically Weak Extracellular Membrane-Adjacent Domain Induces Dimerization of Protocadherin-15. *Biophys J* 115: 2368-2385. <https://doi.org/10.1016/j.bpj.2018.11.010>
- Di Leva F, D'Adamo P, Cubellis MV, D'Eustacchio A, Errichiello M, Saulino C, Auletta G, Giannini P, Donaudy F, Ciccodicola A, Gasparini P, Franze A, Marciano E (2006) Identification of a novel mutation in the myosin VIIA motor domain in a family with autosomal dominant hearing loss (DFNA11). *Audiol Neurootol* 11: 157-64. <https://doi.org/10.1159/000091199>
- DiStefano MT, Hemphill SE, Oza AM, Siegert RK, Grant AR, Hughes MY, Cushman BJ, Azaiez H, Booth KT, Chapin A, Duzkale H, Matsunaga T, Shen J, Zhang W, Kenna M, Schimmenti LA, Tekin M, Rehm HL, Tayoun ANA, Amr SS, ClinGen Hearing Loss Clinical Domain Working G (2019) ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairs. *Genet Med* 21: 2239-2247. <https://doi.org/10.1038/s41436-019-0487-0>
- Downie L, Halliday J, Burt R, Lunke S, Lynch E, Martyn M, Poulakis Z, Gaff C, Sung V, Wake M, Hunter MF, Saunders K, Rose E, Lewis S, Jarmolowicz A, Phelan D, Rehm HL, Melbourne Genomics Health A, Amor DJ (2020) Exome sequencing in infants with congenital hearing impairment: a population-based cohort study. *Eur J Hum Genet* 28: 587-596. <https://doi.org/10.1038/s41431-019-0553-8>
- Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang HY, Speicher KD, Blair IA, Speicher DW, Grosser T, Brass LF (2011) Deciphering the human platelet sheddome. *Blood* 117: e15-26. <https://doi.org/10.1182/blood-2010-05-283838>
- Fowler A, Mahamdallie S, Ruark E, Seal S, Ramsay E, Clarke M, Uddin I, Wylie H, Strydom A, Lunter G, Rahman N (2016) Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN. *Wellcome Open Res* 1: 20. <https://doi.org/10.12688/wellcomeopenres.10069.1>

- Frischmeyer PA, Dietz HC (1999) Nonsense-mediated mRNA decay in health and disease. *Hum Mol Genet* 8: 1893-900. <https://doi.org/10.1093/hmg/8.10.1893>
- Hiller K, Grote A, Scheer M, Munch R, Jahn D (2004) PrediSi: prediction of signal peptides and their cleavage positions. *Nucleic Acids Res* 32: W375-9. <https://doi.org/10.1093/nar/gkh378>
- Hogan MC, Griffin MD, Rossetti S, Torres VE, Ward CJ, Harris PC (2003) PKHD1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression. *Hum Mol Genet* 12: 685-98.
- Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J, Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, Foulkes WD, Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA, Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W (2016) REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet* 99: 877-885. <https://doi.org/10.1016/j.ajhg.2016.08.016>
- Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, Kosmicki JA, Arbelaez J, Cui W, Schwartz GB, Chow ED, Kanterakis E, Gao H, Kia A, Batzoglou S, Sanders SJ, Farh KK (2019) Predicting Splicing from Primary Sequence with Deep Learning. *Cell* 176: 535-548 e24. <https://doi.org/10.1016/j.cell.2018.12.015>
- Jaiganesh A, De-la-Torre P, Patel AA, Termine DJ, Velez-Cortes F, Chen C, Sotomayor M (2018) Zooming in on Cadherin-23: Structural Diversity and Potential Mechanisms of Inherited Deafness. *Structure* 26: 1210-1225 e4. <https://doi.org/10.1016/j.str.2018.06.003>
- Kafita D, Nkhoma P, Dzobo K, Sinkala M (2023) Shedding Light on the Dark Genome: Insights into the Genetic, CRISPR-based, and Pharmacological Dependencies of Human Cancers and Disease Aggressiveness. *bioRxiv*: 2023.08.15.552589. <https://doi.org/10.1101/2023.08.15.552589>
- Kaneko Y, Nakano A, Arimoto Y, Nara K, Mutai H, Matsunaga T (2017) The first sporadic case of DFNA11 identified by next-generation sequencing. *Int J Pediatr Otorhinolaryngol* 100: 183-186. <https://doi.org/10.1016/j.ijporl.2017.07.007>
- Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Genome Aggregation Database C, Neale BM, Daly MJ, MacArthur DG (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581: 434-443. <https://doi.org/10.1038/s41586-020-2308-7>
- Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A (2012) Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. *Bioinformatics* 28: 1647-9. <https://doi.org/10.1093/bioinformatics/bts199>
- Krieger F, Moglich A, Kiefhaber T (2005) Effect of proline and glycine residues on dynamics and barriers of loop formation in polypeptide chains. *J Am Chem Soc* 127: 3346-52. <https://doi.org/10.1021/ja042798i>
- Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG (2007) Clustal W and Clustal X version 2.0. *Bioinformatics* 23: 2947-8. <https://doi.org/10.1093/bioinformatics/btm404>

- Letunic I, Khedkar S, Bork P (2021) SMART: recent updates, new developments and status in 2020. *Nucleic Acids Res* 49: D458-D460. <https://doi.org/10.1093/nar/gkaa937>
- Lewis MA, Schulte J, Matthews L, Vaden KI, Steves CJ, Williams FMK, Schulte BA, Dubno JR, Steel KP (2023) Accurate phenotypic classification and exome sequencing allow identification of novel genes and variants associated with adult-onset hearing loss. *medRxiv*. <https://doi.org/10.1101/2023.04.27.23289040>
- Lezirovitz K, Mingroni-Netto RC (2022) Genetic etiology of non-syndromic hearing loss in Latin America. *Hum Genet* 141: 539-581. <https://doi.org/10.1007/s00439-021-02354-4>
- Love MI, Mysickova A, Sun R, Kalscheuer V, Vingron M, Haas SA (2011) Modeling read counts for CNV detection in exome sequencing data. *Stat Appl Genet Mol Biol* 10. <https://doi.org/10.2202/1544-6115.1732>
- Makrogkikas S, Cheng RK, Lu H, Roy S (2023) A conserved function of Pkhd1l1, a mammalian hair cell stereociliary coat protein, in regulating hearing in zebrafish. *J Neurogenet*: 1-8. <https://doi.org/10.1080/01677063.2023.2187792>
- Maynard DM, Heijnen HF, Horne MK, White JG, Gahl WA (2007) Proteomic analysis of platelet alpha-granules using mass spectrometry. *J Thromb Haemost* 5: 1945-55. <https://doi.org/10.1111/j.1538-7836.2007.02690.x>
- Michalski N, Petit C (2015) Genetics of auditory mechano-electrical transduction. *Pflugers Arch* 467: 49-72. <https://doi.org/10.1007/s00424-014-1552-9>
- Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M (2022) ColabFold: making protein folding accessible to all. *Nat Methods* 19: 679-682. <https://doi.org/10.1038/s41592-022-01488-1>
- Mucha BE, Hennekam RCM, Sisodiya S, Campeau PM (1993) TBC1D24-Related Disorders. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds) *GeneReviews*((R)), Seattle (WA)
- Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. *Genome Res* 11: 863-74. <https://doi.org/10.1101/gr.176601>
- Niu M, McGrath M, Sammon D, Gardner S, Morgan RM, Di Maio A, Liu Y, Bubeck D, Hohenester E (2023) Structure of the transmembrane protein 2 (TMEM2) ectodomain and its apparent lack of hyaluronidase activity. *Wellcome Open Res* 8: 76. <https://doi.org/10.12688/wellcomeopenres.18937.2>
- Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J, Chapin A, Boczek NJ, Schimmenti LA, Murry JB, Hasadsri L, Nara K, Kenna M, Booth KT, Azaiez H, Griffith A, Avraham KB, Kremer H, Rehm HL, Amr SS, Abou Tayoun AN, ClinGen Hearing Loss Clinical Domain Working G (2018) Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss. *Hum Mutat* 39: 1593-1613. <https://doi.org/10.1002/humu.23630>
- Perry J, Redfield S, Oza A, Rouse S, Stewart C, Khela H, Srinivasan T, Albano V, Shearer E, Kenna M (2023) Exome Sequencing Expands the Genetic Diagnostic Spectrum for Pediatric Hearing Loss. *Laryngoscope* 133: 2417-2424. <https://doi.org/10.1002/lary.30507>
- Petit C, Richardson GP (2009) Linking genes underlying deafness to hair-bundle development and function. *Nat Neurosci* 12: 703-10. <https://doi.org/10.1038/nn.2330>
- Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, Wood NW, Hambleton S, Burns SO, Thrasher AJ, Kumararatne D, Doffinger R, Nejentsev S (2012) A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. *Bioinformatics* 28: 2747-54. <https://doi.org/10.1093/bioinformatics/bts526>
- Redfield SE, De-la-Torre P, Zamani M, Khan H, Morris T, Shariati G, Karimi M, Kenna MA, Seo GH, Naz S, Galehdari H, Indzhukulian AA, Shearer AE, Vona B (2023) PKHD1L1, A Gene Involved in the

- Stereociliary Coat, Causes Autosomal Recessive Nonsyndromic Hearing Loss. medRxiv. <https://doi.org/10.1101/2023.10.08.23296081>
- Rehman AU, Friedman TB, Griffith AJ (2017) Unresolved questions regarding human hereditary deafness. *Oral Dis* 23: 551-558. <https://doi.org/10.1111/odi.12516>
- Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M (2019) CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* 47: D886-D894. <https://doi.org/10.1093/nar/gky1016>
- Rockowitz S, LeCompte N, Carmack M, Quitadamo A, Wang L, Park M, Knight D, Sexton E, Smith L, Sheidley B, Field M, Holm IA, Brownstein CA, Agrawal PB, Kornetsky S, Poduri A, Snapper SB, Beggs AH, Yu TW, Williams DA, Sliz P (2020) Children's rare disease cohorts: an integrative research and clinical genomics initiative. *NPJ Genom Med* 5: 29. <https://doi.org/10.1038/s41525-020-0137-0>
- Rouse SL, Florentine MM, Taketa E, Chan DK (2022) Racial and ethnic disparities in genetic testing for hearing loss: a systematic review and synthesis. *Hum Genet* 141: 485-494. <https://doi.org/10.1007/s00439-021-02335-7>
- Santi PA, Anderson CB (1987) A newly identified surface coat on cochlear hair cells. *Hear Res* 27: 47-65. [https://doi.org/10.1016/0378-5955\(87\)90025-6](https://doi.org/10.1016/0378-5955(87)90025-6)
- Sato S, Miyazaki M, Fukuda S, Mizutani Y, Mizukami Y, Higashiyama S, Inoue S (2023) Human TMEM2 is not a catalytic hyaluronidase, but a regulator of hyaluronan metabolism via HYBID (KIAA1199/CEMIP) and HAS2 expression. *J Biol Chem* 299: 104826. <https://doi.org/10.1016/j.jbc.2023.104826>
- Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* 11: 361-2. <https://doi.org/10.1038/nmeth.2890>
- Shearer AE, Smith RJ (2015) Massively Parallel Sequencing for Genetic Diagnosis of Hearing Loss: The New Standard of Care. *Otolaryngol Head Neck Surg* 153: 175-82. <https://doi.org/10.1177/0194599815591156>
- Shihab HA, Gough J, Mort M, Cooper DN, Day IN, Gaunt TR (2014) Ranking non-synonymous single nucleotide polymorphisms based on disease concepts. *Hum Genomics* 8: 11. <https://doi.org/10.1186/1479-7364-8-11>
- Slepecky N, Chamberlain SC (1985) The cell coat of inner ear sensory and supporting cells as demonstrated by ruthenium red. *Hear Res* 17: 281-8. [https://doi.org/10.1016/0378-5955\(85\)90072-3](https://doi.org/10.1016/0378-5955(85)90072-3)
- Sloan-Heggen CM, Bierer AO, Shearer AE, Kolbe DL, Nishimura CJ, Frees KL, Ephraim SS, Shibata SB, Booth KT, Campbell CA, Ranum PT, Weaver AE, Black-Ziegelbein EA, Wang D, Azaiez H, Smith RJH (2016) Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing loss. *Hum Genet* 135: 441-450. <https://doi.org/10.1007/s00439-016-1648-8>
- Smith RJ, Bale JF, Jr., White KR (2005) Sensorineural hearing loss in children. *Lancet* 365: 879-90. [https://doi.org/10.1016/S0140-6736\(05\)71047-3](https://doi.org/10.1016/S0140-6736(05)71047-3)
- Vona B, Hofrichter MA, Neuner C, Schroder J, Gehrig A, Hennermann JB, Kraus F, Shehata-Dieler W, Klopocki E, Nanda I, Haaf T (2015) DFNB16 is a frequent cause of congenital hearing impairment: implementation of STRC mutation analysis in routine diagnostics. *Clin Genet* 87: 49-55. <https://doi.org/10.1111/cge.12332>
- Vona B, Mazaheri N, Lin SJ, Dunbar LA, Maroofian R, Azaiez H, Booth KT, Vitry S, Rad A, Ruschendorf F, Varshney P, Fowler B, Beetz C, Alagramam KN, Murphy D, Shariati G, Sedaghat A, Houlden H, Petree C, VijayKumar S, Smith RJH, Haaf T, El-Amraoui A, Bowl MR, Varshney GK, Galehdari H (2021) A biallelic variant in CLRN2 causes non-syndromic hearing loss in humans. *Hum Genet* 140: 915-931. <https://doi.org/10.1007/s00439-020-02254-z>

- Wang L, Chen Q, Liu T, Bai T, Zhang M, Hu Y, Li J, Chang F (2023) Role and mechanism of benzo[a]pyrene in the transformation of chronic obstructive pulmonary disease into lung adenocarcinoma. *J Cancer Res Clin Oncol* 149: 4741-4760. <https://doi.org/10.1007/s00432-022-04353-y>
- Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C (2019) MetaDome: Pathogenicity analysis of genetic variants through aggregation of homologous human protein domains. *Hum Mutat* 40: 1030-1038. <https://doi.org/10.1002/humu.23798>
- Wu X, Ivanchenko MV, Al Jandal H, Cicconet M, Indzhykilian AA, Corey DP (2019) PKHD1L1 is a coat protein of hair-cell stereocilia and is required for normal hearing. *Nat Commun* 10: 3801. <https://doi.org/10.1038/s41467-019-11712-w>
- Yamamoto H, Tobisawa Y, Inubushi T, Irie F, Ohyama C, Yamaguchi Y (2017) A mammalian homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after cell-surface hyaluronidase. *J Biol Chem* 292: 7304-7313. <https://doi.org/10.1074/jbc.M116.770149>
- Yang Y, Pang Q, Hua M, Huangfu Z, Yan R, Liu W, Zhang W, Shi X, Xu Y, Shi J (2023) Excavation of diagnostic biomarkers and construction of prognostic model for clear cell renal cell carcinoma based on urine proteomics. *Front Oncol* 13: 1170567. <https://doi.org/10.3389/fonc.2023.1170567>
- Yoshida H, Nagaoka A, Kusaka-Kikushima A, Tobiishi M, Kawabata K, Sayo T, Sakai S, Sugiyama Y, Enomoto H, Okada Y, Inoue S (2013) KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. *Proc Natl Acad Sci U S A* 110: 5612-7. <https://doi.org/10.1073/pnas.1215432110>
- Yu J, Wang G, Chen Z, Wan L, Zhou J, Cai J, Liu X, Wang Y (2023) Deficit of PKHD1L1 in the dentate gyrus increases seizure susceptibility in mice. *Hum Mol Genet* 32: 506-519. <https://doi.org/10.1093/hmg/ddac220>
- Zeng B, Xu H, Tian Y, Lin Q, Feng H, Zhang Z, Li S, Tang W (2022a) A novel splicing variant in the TMC1 gene causes non-syndromic hearing loss in a Chinese family. *Chin Med J (Engl)* 135: 2631-2633. <https://doi.org/10.1097/CM9.0000000000001966>
- Zeng B, Xu H, Yu Y, Li S, Tian Y, Li T, Yang Z, Wang H, Wang G, Chang M, Tang W (2022b) Increased diagnostic yield in a cohort of hearing loss families using a comprehensive stepwise strategy of molecular testing. *Front Genet* 13: 1057293. <https://doi.org/10.3389/fgene.2022.1057293>
- Zheng C, Quan R, Xia EJ, Bhandari A, Zhang X (2019) Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression. *Oncol Lett* 18: 3227-3235. <https://doi.org/10.3892/ol.2019.10632>

Statements and Declarations

Acknowledgments

We thank the families for their participation. We thank Mahdiyeh Behnam for support with CNV analysis for the proband in Family 3.

Funding

This work was supported by NIDCD K08 DC019716 to AES, the De Garay Family Fund to MAK with support from the Boston Children's Rare Disease Cohort Initiative, and the German Research Foundation (DFG) VO 2138/7-1 grant 469177153 to BV, and by NIH R01DC017166 (NIDCD) and R01DC020190 (NIDCD) to AAI. Funding for work in Pakistan was provided by the University of the Punjab (SN).

Author contributions

SER and PD contributed equally as shared first authors, MZ and HW contributed equally as second authors, and AAI, AES and BV contributed equally as shared last authors. AES, PD, and AAI conceived the study. PD, TM, and AAI designed methodology. PD and TM contributed software. MZ, PD, and AAI performed formal analyses that were validated by HG, MK, PD, TM, and AAI. MZ, HW, HK, MK, SN, MAK, PD, TM, AAI, and BV conducted the investigation process. HG, GS, MAK, HX, WL, AES, SER, and PD secured patient and experimental resources. MZ, HW, HG, GS, BV, SER, WL, AES, PD, and AAI performed data curation. BV, AES, PD, and AAI wrote the original draft. MZ, HK, MK, SN, HG, BV, SER, AES, PD, and AAI contributed to reviewing and editing. BV, AES, SER, PD, and AAI prepared figures. SN, AES, PD, and AAI provided supervision. BV, AES, and AAI oversaw project administration. All authors reviewed and approved of the manuscript.

Data Availability

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Compliance with ethical standards

Conflict of interest

Go Hun Seo is an employee of 3Billion, Inc. The other authors have no conflicts to declare.

Ethics approval

This study was approved by the institutional review boards of Boston Children's Hospital (IRB P-00031494), University Medical Center Göttingen (No. 3/2/16), and the School of Biological Sciences, University of Punjab, Lahore, Pakistan (IRB No. 00005281).

Consent to participate

Written informed consent was obtained from all participants.

Consent to publish

Consent to publish was obtained from all participants.

Figures




Fig. 1. Pedigrees & Audiograms. Pedigree and audiometric information for four families with biallelic *PKHD1L1* variations (a) Pedigrees for families 1-4. Each proband with SNHL is indicated with shading and arrow. (b) Pure tone audiometry for probands 1-4; x represents results for the left ear and o represents the right. Audiometric evaluation performed at ages ranging between 8 and 13 years-old for probands.




Fig. 2. PKHD1L1 protein domain prediction and evolutionary analysis. (a) Schematic of a hair-cell stereocilia bundle under force stimulation highlighting the stereocilia surface coat. (b) Protein domain composition prediction from SMART using the *Hs* PKHD1L1 protein sequence as in NCBI accession code NP_803875.2, including the signal peptide (20 amino acids are predicted for *Hs* PKHD1L1 according to SMART. See Supplementary Table S1). Positions of each missense variant reported in this study is presented with a green arrowhead. The red star represents a newly predicted TMEM2-like domain. Black and purple arrow-headed lines represent the sequence fragments used for AlphaFold2 modelling of IPT1-2, IPT5-6, and TMEM2-like domain, respectively. (c) Topological description of *Hs* PKHD1L1 protein sequence as a reference. (d-e) Multiple protein sequence alignments comparing IPT1 and IPT6 domains among 10 different PKHD1L1 orthologs, respectively (see Supplementary Table S1 for details about the selected species and Supplementary Fig. S3 for full PKHD1L1 sequence alignment). IPT1 has a pairwise sequence identity conservation of 82.3%, while IPT6 has a pairwise sequence identity of 74.9% across 10 different orthologs. An independent % sequence identity analysis of only *Hs* and *Mm* species for IPT1 and IPT6 shows 82.9% and 77.8%, respectively (sequence alignment not shown). Missense variants are highlighted by green triangles. Blue circles represent cysteine residues forming disulfide bonds showed in figure 2 d-e. Each alignment was color-coded for sequence similarity (35% threshold) using Jalview. White-colored residues report the lowest similarity and dark blue report the highest (see Methods). PKHD1L1 orthologs were chosen based on sequence availability and taxonomical diversity (Choudhary et al. 2020; De-la-Torre et al. 2018; Jaiganesh et al. 2018).




Fig. 3. AlphaFold2 modelling of PKHD1L1 protein fragments carrying Gly120Ser and Gly1314Val mutations. (a) Superposed AlphaFold2 models of both native *Hs* IPT1-2 (orange) and *Hs* IPT1-2 p.(Gly120Ser) variant (mauve) are shown. (b) Higher magnification image of the mutated site. p.S129 in lime and p.G129 in cyan. No apparent structural changes are predicted by AlphaFold2. (c) Structural model of *Hs* IPT5-6 showing the native Gly1314 position. (d) Superposed *Hs* IPT5-6 (orange) and *Hs* IPT5-6 p.(Gly1314Val) (mauve) structures showing a structural change predicted by AlphaFold2 as a result of p.(Gly1314Val) substitution. β -strands and loops do not overlap, with a dashed black arrow reporting the loop shift. (e) Higher

magnification image of the mutated site showing the conformation change of β -strands and loops. p.V1314 (lime) cause steric hindrance in the area inducing an expanded conformation to the variant structure in mauve. See dashed arrows.




Fig. 4. PKHD1L1 structural modelling of the protein fragment containing the p.(His2479Gln) variant. Based on AlphaFold2 predictions, this fragment of PKHD1L1 shares a

common fold with the TMEM2 protein within the region carrying the p.(His2479Gln) variant. (a) Protein sequence alignment of a protein segment of *Hs* TMEM2 against 10 different PKHD1L1 orthologs (See Supplementary Table S1 for details of the selected species, Supplementary Fig. S4 for sequence alignment of this specific fragment, and Supplementary Fig. S3 for full PKHD1L1 sequence alignment). Residue numbering for TMEM2 as in PDB: 8C6I (Niu et al. 2023), while residue numbering for *Hs* PKHD1L1 as in NCBI accession code NP_803875.2 with the signal peptide included (Supplementary Table S1, 26 residues are suggested according to protein sequence alignment, see Methods). Green triangles point to the location of the *Hs* p.(His2479Gln) variant, orange circles (*left*) indicate 100% amino acid sequence identity for this PKHD1L1 fragment between the *Hs*, *Pt*, and *Mm2* species (See supplementary Table S1 for details about the selected orthologs). Green circles represent depicted residues in panels b-e. The alignment was color-coded for sequence similarity (35% threshold) using Jalview. White-colored residues show the lowest similarity and dark blue report the highest (see Methods). PKHD1L1 orthologs were chosen based on sequence availability and taxonomical diversity. (b) The simulated protein structure covering the protein fragment highlighted by purple arrow-headed line in Fig. 2b. Front view of the structure showing IPT14 linked to the PKHD1L1 TMEM2-like domain. The red star points to the linker connection. Residues at the mutation site are depicted as cyan sticks. (c) Side view from *panel a* showing a clear view of the stacked β -strand motifs. (d) Superposed structural protein alignment between WT *Hs* PKHD1L1 TMEM2-like domain model (orange) with the X-ray crystal structure of *Hs* TMEM2 protein (PDB: 8C6I, magenta). Residues at the native TMEM2-histidine finger site are depicted as green sticks. (e) Higher magnification image of the potential conserved histidine-finger site between PKHD1L1 (orange) and TMEM2 (magenta) protein fragments and the Ni²⁺ ion shown as lime sphere. (f) Displayed residues between both proteins surrounding the Ni²⁺-ion site highlighted in *panel a* in green circles.




Fig. 5. Thermodynamic and folding stability evaluation of two missense variants using NanoDSF. (a) NanoDSF melting temperatures for WT *Mm* IPT1-3 (orange) and *Mm* IPT1-3 p.(Gly129Ser) variant (pink). Measurements show at least three T_m peaks (orange dotted line)

for the WT IPT1-3, likely because the protein fragment includes multiple IPT domains that unfold sequentially. Measured T_m values are shifted to the left (pink dotted line) showing a decrease of the thermal folding stability. Temperatures are labeled for each T_m transition point. (b) Results for WT *Mm* IPT5-6 and *Mm* IPT5-6 p.(Gly1314Val) showing a reduced thermal stability (2 replicates, see Methods section). Traces correspond to the normalized first derivate of the fluorescence ratio showing the inflection point of the fluorescence ratio, which corresponds to the melting temperature of the sample. T_{onset} values and protein purification experiments are shown in Supplementary Fig. S5.




Fig. 6. Minigene splicing assay for evaluation of the functional effect of p.(Gly605Arg) on splicing. (a) Schematic demonstrating designed minigene assay including CMV promoter, mutation location, and primers. (b) Schematic showing calculated size of fragment with exon 17 included (533 bp) or excluded (389 bp). (c) and (d) RT-PCR result from HEK293 and HeLa cells transfected with both WT and mutant plasmids showing different fragment lengths as well as sequence on chromatogram demonstrating lack of incorporation of exon 17 in cells transfected with the mutant plasmid, leading to in-frame deletion of 48 amino acids (p.Val557_Arg604del) using the NCBI NP_803875.2 as a reference sequence.

Table 1. *PKHD1L1* variants identified.

F	Chr8 Genomic location (g.)	cDNA (c.)	Protein (p.)	Zyg	AF gnomAD (v.3.1.2)	MAF gnomAD (v3.1.2)	MAF Pop gnomAD (v3.1.2)	AF gnomAD (v.2.1.1)	MAF gnomAD (v.2.1.1)	MAF Pop gnomAD (v2.1.1)	TOPMed v8	All-of-Us	SIFT	PP-2	FATHMM	MT	REVEL	CADD
1	109382539G>A	385G>A	Gly129Ser	Het	6.6e-6	1.5e-5	European (non-Finnish)	-	-	-	3.7e-6	6.0e-6	0 ¹	0.995 ¹	-2.15 ¹	0.99 ¹	0.55 ²	26.2 ¹
1	109439077G>T	3941G>T	Gly1314Val	Het	3.7e-4	7.2e-4	Ashkenazi Jewish	2.8e-4	5.7e-4	European (non-Finnish)	3.7e-4	3.5e-4	0.004 ¹	0.98 ¹	-2.56 ¹	1 ¹	0.86 ¹	26.6 ¹
2	109491899C>T	10141C>T	Arg3381Ter	Hom	2.0e-5	1.9e-4	East Asian	4.3e-5	2.1e-4	East Asian	5.3e-5	4.1e-5	-	-	-	1 ¹	-	39.0 ¹
3	109464269C>A	7437C>A	His2479Gln	Hom	9.9e-5	3.1e-3	South Asian	2.2e-4	1.8e-3	South Asian	2.6e-5	1.8e-5	0 ¹	0.88 ¹	-3.30 ¹	0.04 ³	0.72 ¹	22.9 ¹
4	109406478G>A*	c.1813G>A	Gly605Arg	Het	1.3e-5	1.9e-4	East Asian	5.9e-5	7.8e-4	East Asian	1.9e-5	-	0.009 ¹	-	-2.43 ¹	0.99 ¹	0.75 ¹	33.0 ¹
4	109466608del17c.8452_8468del	Leu2818TyrfsTer5	Ter5	Het	2.6e-5	7.7e-4	East Asian	7.3e-5	1.0e-3	East Asian	6.8e-5	2.6e-5	-	-	-	-	-	34.0 ¹

All variants are annotated according to NC_000008.11 (genomic) and NM_177531.6 (coding DNA). Residue position according to NP_803875.2 including the signal peptide (Supplementary Table S1). Abbreviations: AF, allele frequency; chr, chromosome; F, family; MAF, maximum allele frequency; MT, MutationTaster; Pop, population; PP2, PolyPhen-2; Zyg, zygosity. Pathogenicity is represented as ¹deleterious, ²neutral, or ³benign prediction, whereas “-” represents variant not scored.*109406478G>A is predicted by SpliceAI to affect splicing: 0.230 (donor_gain).